Full text is available at the source.
Abstract
SARS-CoV-2 infection is associated with 3- to 5-fold increases in cardiovascular events during the acute phase.
- Myocarditis risk is higher for males (RR 4.44) and females (RR 5.59) following SARS-CoV-2 infection.
- All-cause mortality risk increases for males (RR 4.53) during the acute phase of infection.
- BNT162b2 vaccination results in 65-76% reductions in major adverse cardiovascular events within the first three months.
- Post-infection vaccination (hybrid immunity) leads to an additional 36-38% reduction in major adverse cardiovascular events.
- Completing the two-dose vaccination series reduces mortality by 77% and myocarditis by 62% compared to single dosing.
- SARS-CoV-2 infection presents a greater and more sustained cardiovascular risk than BNT162b2 vaccination across all groups.
Simplified
mRNA Technology